Business Overview:
Cancer Therapeutics Drug developer is seeking partner(s) who are capable of bringing $5 to $25 million or more (in 3 phases) to the partnership. The company was founded in the early nineties and is at the stage of transitioning from pre-clinical studies to clinical studies. In addition the company will be presenting the experimental results of its technology to Top Pharmaceutical companies to seek suitable alliances.
TECHNOLOGY HIGHLIGHTS: In essence company's technology may be summarized as follows: Development of cancer therapies designed to selectively stop the proliferation of cancer cells by targeting the molecular alterations responsible for their malignant transformation while minimally affecting normal cells. The company's lead drug candidates, which were licensed from a leading Ivy League University , are inhibitors of mRNA translation at the level of initiation, and abrogate growth of human cancer cell lines and xenografted human tumors in mice with high potency and minimal or no toxicity.
For more information regarding this listing please contact us by completing the "Contact the Seller" form to the left. We look forward to hearing from you.
Property Features and Assets:
Not Applicable
Market Competition and Expansion:
Very significant driven by the needs of the aging population of the world and the need of large pharmaceutical companies to roll-out patented technologies for cancer curing drugs.
Additional Details:
- The property is owned.
- The owner is willing to train/assist the new owner.
- This is not a homebased business opportunity.
- This is not a franchise resale opportunity.
Resources: